MEDVi GLP-1 Reviews and Complaints 2026: A Comprehensive Analysis
MEDVi is an AI-powered telehealth platform selling compounded GLP-1 weight loss medications, founded in September 2024 by Matthew Gallagher. The company generated **$401 million in revenue in 2025** with a net profit of $65 million — a 16.2% margin — while operating with a headcount of just two people. The platform is now on track for $1.8 billion in annual sales in 2026. MEDVi holds LegitScript certification, has 11,400+ Trustpilot reviews with a 4.4–4.5 average rating, and was independently verified by The New York Times for its financial claims.
However, the platform has accumulated a series of serious regulatory and legal problems. MEDVi received an FDA Warning Letter in February 2026 for misbranding compounded semaglutide and tirzepatide products. Its clinical partner OpenLoop Health suffered a data breach in January 2026 exposing 1.6 million patient records. A class action lawsuit was filed in Delaware in November 2025 regarding compounded oral tirzepatide. Investigations have documented AI-generated fake doctors, fabricated before-and-after photos, and hundreds of fake Facebook accounts posing as physicians. Consumer complaints about billing, auto-renewal, and cancellation are widespread.
Review Summary Box
| Feature | Details |
|---|---|
| Overall Rating | 2.5 / 5 ⭐ |
| Best For | Self-sufficient patients who want low-cost compounded GLP-1 access and will verify all terms before enrolling |
| Not For | Anyone who wants FDA-approved products, responsive customer support, or a company with a clean regulatory record |
| Product Type | Telehealth Platform (GLP-1 Weight Management) |
| Key Medications | Compounded semaglutide (injection and oral tablet), compounded tirzepatide (injection and oral tablet) |
| Compounded Semaglutide Injection | $179 first month → $299/month ongoing |
| Compounded Semaglutide Tablet | $249/month |
| Compounded Tirzepatide Injection | From $349/month |
| Compounded Tirzepatide Tablet | $279/month |
| Billing Cycle | Every 28 days (13 charges per year) |
| Refund Policy | Results-based guarantee requiring 5 months of program participation; deducts 25% consultation fee |
| States Served | All 50 states |
| Insurance | Not accepted |
| LegitScript | Certified |
| BBB Rating | F (not accredited) |
| Trustpilot Rating | 4.4–4.5/5 across 11,400+ reviews (main page); 2.3/5 on the GLP subdomain |
| FDA Warning Letter | February 20, 2026 — misbranding violations |
| Data Breach | January 2026 — OpenLoop exposed 1.6 million patient records |
| Class Action | Filed November 2025 — compounded oral tirzepatide marketing |
What Is MEDVi?
MEDVi is a direct-to-consumer telehealth platform that connects patients with licensed clinicians who prescribe compounded GLP-1 medications for weight management. The company was founded in September 2024 by Matthew Gallagher, a 41-year-old entrepreneur who built the platform with $20,000 in starting capital and a collection of AI tools including ChatGPT, Claude, Grok, Midjourney, Runway, and ElevenLabs.
The Corporate Structure
MEDVi’s architecture is deliberately thin. Two infrastructure platforms — CareValidate and OpenLoop Health — provide the licensed physicians, prescription processing, pharmacy fulfillment, shipping logistics, and regulatory compliance. MEDVi owns only the customer relationship: branding, website, paid media, checkout flow, and customer service.
This means MEDVi is not itself a healthcare provider or a pharmacy. It is a marketing and customer-acquisition layer sitting on top of a white-label telehealth infrastructure.
The AI-Powered Operations
Gallagher used AI to build the entire platform. He used ChatGPT, Claude, and Grok to write the code. Midjourney and Runway generated ad creative. ElevenLabs supplied voice tools. Custom AI agents connected his systems, and a chatbot handled inbound service inquiries.
The AI implementation had notable failures. The customer service chatbot initially fabricated drug prices, and Gallagher honored those quotes. It also hallucinated product lines that did not exist, claiming MEDVi sold hair-loss drugs before any such offering launched.
The Financial Performance
| Metric | 2025 | 2026 (Projected) |
|---|---|---|
| Revenue | $401 million | $1.8 billion |
| Net Profit | $65 million | Not disclosed |
| Net Margin | 16.2% | Not disclosed |
| Customers | 250,000 | Not disclosed |
| Employees | 2 | 2 |
For comparison, Hims & Hers reported $2.4 billion in revenue in 2025 with 2,442 employees and a 5.5% net margin. Gallagher is running nearly three times the margin with a headcount of two.
What Medications Does MEDVi Prescribe?
MEDVi offers compounded semaglutide and compounded tirzepatide in both injectable and oral tablet formats.
Compounded Semaglutide Injection
| Detail | Information |
|---|---|
| Format | Weekly subcutaneous injection |
| First Month | $179 |
| Ongoing | $299/month |
| Price Changes with Dose | No — locked at $299 regardless of dose escalation |
Compounded Semaglutide Tablet
| Detail | Information |
|---|---|
| Format | Daily oral tablet |
| Price | $249/month |
Compounded Tirzepatide Injection
| Detail | Information |
|---|---|
| Format | Weekly subcutaneous injection |
| Price | From $349/month |
Compounded Tirzepatide Tablet
| Detail | Information |
|---|---|
| Format | Daily oral tablet |
| Price | $279/month |
The Critical Distinction
No compounded GLP-1 medication is FDA-approved. The FDA does not review compounded preparations before marketing for safety, effectiveness, or quality. Compounded drugs are not generic equivalents of FDA-approved branded medications such as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA specifically cited MEDVi for claiming “Same active ingredient as Wegovy® and Ozempic®” and “Same active ingredient as Mounjaro® and Zepbound®” — claims the agency said falsely imply FDA approval or evaluation.
How Does MEDVi Work?
The process follows a fully remote telehealth model.
The Intake Process
- Complete an online health questionnaire — a single long scrollable page covering health history, current medications, and weight-loss goals. No photo ID is required at this stage.
- Pay for your first month — payment is required before the consultation. The first-month price is discounted ($179 for compounded semaglutide injections, $249 for semaglutide tablets, $279 for tirzepatide). The ongoing monthly rate is not clearly disclosed at checkout — it is buried in the FAQ at the bottom of the page.
- Schedule a mandatory video consultation — unlike clinics that handle consultations asynchronously, MEDVi requires a virtual video visit. This format can delay treatment by a day or two.
- Complete the video visit — the patient portal automatically takes a photo of your face for identity verification. One tester described the doctor as “warm, genuinely engaged, and ensured I knew enough about the medication before proceeding”.
- Review your appointment recap — a recap appears in the patient portal in both English and Spanish.
- Medication ships to your home — fulfillment is handled through OpenLoop Health and partner pharmacies.
The Billing Cycle
MEDVi bills automatically every 28 days — not monthly. This means 13 billing cycles per year, not 12. The RX Index notes that both MEDVi and Remedy Meds use this cycle, “and we’ll show you the math”.
Cancellation Requirements
Cancellation requires 72 hours notice before the billing date. The RX Index states: “Must be in plain English before you buy”. Cancellation can be done through the patient portal or by contacting customer service.
Refund Policy
MEDVi’s refund policy is results-based and restrictive:
- Eligibility: You must demonstrate that you have not lost weight after following the program for a minimum of 5 months
- Deduction: The refund deducts 25% for doctor consultation fees
- Prescription products: No refunds on prescription products once ordered
This means a patient who wants a refund must complete five months of the program, document no weight loss, and still forfeit a quarter of what they paid.
User Reviews and Feedback
The Trustpilot Rating Discrepancy
MEDVi’s review profile is unusually fragmented across platforms and even within Trustpilot itself:
| Platform | Rating | Review Count |
|---|---|---|
| Trustpilot (main) | 4.4–4.5/5 | 11,400+ |
| Trustpilot (GLP subdomain) | 2.3/5 | Not disclosed |
| ConsumerAffairs | 3.6/5 | ~1,600 |
| BBB | F rating | Not accredited |
The main Trustpilot page shows a strong 4.4–4.5 rating, but the MEDVI GLP subdomain shows a “Poor” 2.3/5 rating. The BBB rating is F, and a LinkedIn analysis noted “Trustpilot: 1.2 out of 5” for a related entity.
Positive Experiences
“My experience has been great!”
“Customer service was wonderful both by email and by phone. GLP1 has definitely helped me get out of the pre-diabetic range. I feel the price is fair… Highly recommend if you’re considering GLP-1.” — ConsumerAffairs reviewer
“The doctor was warm and engaged”
“My doctor was warm, genuinely engaged, and ensured I knew enough about the medication before proceeding. She even proactively included a nausea prescription just in case.” — NutritionNC firsthand tester
“Flat-rate pricing with no membership fee”
“Flat-rate pricing with no membership fee. Lifestyle coaching included at no extra cost. Lab work included but not required. Chat support is responsive and human. Near-perfect legitimacy credentials.” — NutritionNC review summary
Negative Experiences
“This is a scam”
“They will charge you for tirzepitide and then say you qualify for semaglutide. There is a significant difference in cost. They will not acknowledge this.” — Trustpilot reviewer, January 2026
“Charged me $900 after I told them to cancel”
“Marginally effective drug but I requested to cancel after three months and they charged me anyway. Now I have to dispute the charge with my credit card company. Scam alert!” — Trustpilot reviewer, December 2025
“Bait and switch runaround”
“The product was supposed to arrive Feb 13. It’s refrigerated and for that reason sent overnight. It’s the 15th and still nothing. FedEx has been unresponsive. Zero info. So I called and asked for a replacement or a refund. They declined both.” — Trustpilot reviewer, February 2026
“Buyer beware!”
“They offered me tirzepatide@199 a month (that’s how they market it). After the first month I place a re-order and got billed for $399. They told me that the first was an introductory price… I got no notice of the new price until after I renewed and was charged. RIPOFF!!” — Trustpilot reviewer, December 2025
“Did not work and I lost $600”
“The medicine did not work on me. I did not lose 1 pound. It made my arm break out and a serious rash. They agreed to give me a refund, but then changed their mind and denied it.” — Trustpilot reviewer, December 2025
“I ordered GLP-1s from MEDVi… serious transparency problems”
“Ads show first-month price only. Real pricing buried in FAQ fine print. Unverifiable media endorsement claims. Some before-and-after photos look artificial. No explanation of oral vs. injectable differences.” — NutritionNC review
Summary of User Trends
The positive reviews frequently mention:
- Responsive chat support
- Warm, engaged video consultations
- Flat-rate pricing (when the patient understands it)
- Lifestyle coaching included at no extra cost
- Lab work included but not required
The negative reviews consistently cite:
- Bait-and-switch pricing — first month at $179, then $299 or $349
- Charges after cancellation — customers billed despite requesting cancellation
- Refund denials — refunds promised then denied
- Shipping failures — medication not arriving, especially refrigerated products
- No results — medication ineffective for some patients
- Side effects — rashes, nausea, and other adverse reactions
The FDA Warning Letter: Misbranding Violations
On February 20, 2026, the FDA issued a Warning Letter to MEDVi, LLC (MARCS-CMS 721455). The letter cited multiple violations of the Federal Food, Drug, and Cosmetic Act.
Violation 1: False Representation as the Compounder
The FDA stated: “The compounded semaglutide and tirzepatide products displayed on your website identify ‘MEDVi’ on the pictured label, suggesting MEDVi is the compounder of those drugs when in fact it is not”.
Violation 2: Misleading FDA Approval Claims
The FDA cited the following claims on MEDVi’s website:
- “Same active ingredient as Wegovy® and Ozempic®”
- “Same active ingredient as Mounjaro® and Zepbound®”
The FDA stated: “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not”.
What This Means
The FDA warning letter is not a safety determination. It is a marketing-language and labeling enforcement action. The FDA put MEDVi on notice that its claims are false or misleading and that its compounded products are misbranded under federal law. The agency stated: “The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations”.
The Data Breach: 1.6 Million Patient Records
In January 2026, OpenLoop Health — MEDVi’s clinical partner and the infrastructure provider handling its physician network and prescription fulfillment — suffered a data breach exposing 1.6 million patient records.
What Was Exposed
According to reports, a threat actor claimed to have stolen 1.6 million patient records from OpenLoop Health. One security researcher discovered that changing a number in the URL allowed access to the complete medical record of any patient — including name and weight.
Additional Exposure
A separate security finding revealed that MEDVi hardcoded 999 patient email addresses in public JavaScript on its website. The same bundle also exposed:
- A list of Season Health (MEDVi’s parent company) employee emails used to bypass checkout flows
- A separate list of OpenLoop Health staff emails used to bypass intake form logic
Both were labeled as such in the source code.
Why This Matters
Patients who enrolled in MEDVi’s GLP-1 program may have had their personal health information exposed through a vendor breach they never chose. The data breach is a consequence of MEDVi’s thin infrastructure model — it outsourced clinical operations to OpenLoop without maintaining direct control over data security.
The Class Action Lawsuit: Compounded Oral Tirzepatide
A class action lawsuit was filed in Delaware in November 2025 (Day v. OpenLoop Health Inc., D. Del., 1:25-cv-01418) regarding compounded oral tirzepatide sold through MEDVi’s website.
The Allegations
The plaintiff, Darby Day, alleges he purchased a one-month supply of compounded oral tirzepatide pills through MEDVi for $279.99. The lawsuit claims:
- Compounded oral tirzepatide requires FDA approval, and without FDA approval, pharmacies are prohibited from lawfully selling it
- The product was “falsely represented as a safe and effective GLP-1 medication comparable to” FDA-approved alternatives
- The defendants “received and retained payments from consumers” for a product that was not what it was represented to be
The “Snake Oil” Characterization
A February 2026 Fierce Healthcare report described the lawsuit as being over “snake oil” compounded oral GLP-1. The report noted that the consumer’s purchase from MEDVi “functions as an order routed through OpenLoop’s telehealth system and fulfilled by Triad Rx”.
Why This Matters
Oral tirzepatide is marketed as a needle-free alternative to injections. If the oral formulation does not deliver therapeutic levels of the active ingredient — and if it was sold without the FDA approval that its manufacturers would require — patients paid for a product that may not work and was marketed illegally.
The Fake Doctors and Fabricated Marketing
MEDVi’s marketing has been the subject of multiple independent investigations documenting fabricated credibility signals.
AI-Generated Fake Doctors
Business Insider investigations found that MEDVi’s advertising on Meta platforms was “fueled by ads from doctors who don’t appear to exist.” As of April 2026, at least six purported doctor pages were marketing MEDVi’s weight-loss drugs and a sexual performance product.
Futurism reported that MEDVi “plastered its website with AI-deepfaked images of phony patients passed off as the real deal” and featured “images of AI-generated doctors in MEDVi-branded lab coats”.
800+ Fake Facebook Accounts
Multiple reports state that MEDVi’s growth “may have been pushed by 800+ Facebook accounts posing as doctors“.
Fabricated Before-and-After Photos
A Yahoo Finance investigation found that one before-and-after photo on MEDVi’s site showed a customer identified as “Michael P,” who it said had lost 48 pounds while achieving “17 percent increased muscle” and “55 percent sleep improvement.” The photo was actually taken from a random Redditor who lost weight in the mid-2010s — long before GLP-1s were used for weight loss — after giving up alcohol.
Fake Doctor Endorsements
When Yahoo Finance contacted one of the doctors MEDVi claimed to be working with, he told them he had no involvement with the company and demanded that it “remove me from their sites”.
The Forbes and NYT Coverage
Forbes published a glowing profile of MEDVi, focusing on how Gallagher built a $1.8 billion company with $20,000 and AI. The New York Times also profiled the company favorably. Neither outlet mentioned the FDA warning letter, the data breach, or the fake doctor allegations in their initial coverage. A later Yahoo Finance investigation criticized the NYT for “laundering the reputation” of a company using “a dishonest dumpster fire of fake doctors, phony before-and-after pictures, and other glaring red flags”.
Pricing Analysis
The True Cost of MEDVi
| Medication | First Month | Ongoing | Annual Cost (13 Cycles) |
|---|---|---|---|
| Compounded Semaglutide Injection | $179 | $299/month | $3,767 |
| Compounded Semaglutide Tablet | $249 | $249/month | $3,237 |
| Compounded Tirzepatide Injection | $349 | $349/month | $4,537 |
| Compounded Tirzepatide Tablet | $279 | $279/month | $3,627 |
Note: These annual costs are based on 13 billing cycles per year, not 12, because MEDVi bills every 28 days.
The Pricing Transparency Problem
MEDVi’s advertising prominently features the first-month price — $179 for compounded semaglutide. The ongoing monthly rate is buried in the FAQ at the bottom of the page. One firsthand tester wrote: “The ongoing monthly rate is higher, but, frustratingly, you will not see that clearly disclosed at checkout. It is buried in the FAQ at the bottom of the page”.
Multiple Trustpilot reviewers describe being “bait and switched” — charged $399 after being quoted $199 or $299.
Cost Comparison
| Provider | Semaglutide | Tirzepatide | Notes |
|---|---|---|---|
| MEDVi | $179 first → $299/mo | From $349/mo | Oral tablets available |
| Remedy Meds | $299/mo flat | $399/mo flat | Flat at all doses |
| Hims | $199/mo | Varies | — |
| Henry Meds | $199/mo | Varies | LegitScript certified |
| Eden | $129/mo | Varies | Money-back warranty |
At $299/month ongoing, MEDVi is competitively priced but not the cheapest option. The first-month discount is attractive but obscures the true ongoing cost.
Safety and Regulatory Considerations
Compounded GLP-1 Products Are Not FDA-Approved
No compounded GLP-1 medication is FDA-approved. The FDA does not review compounded preparations before marketing for safety, effectiveness, or quality. Compounded drugs are not generic equivalents of FDA-approved branded medications. This is standard across all compounded GLP-1 providers, not unique to MEDVi.
The FDA Warning Letter
MEDVi received a Warning Letter from the FDA on February 20, 2026, for misbranding violations related to its compounded semaglutide and tirzepatide products. The letter cited false claims of FDA approval, false representation as the compounder, and misleading marketing language.
The Data Breach
OpenLoop Health, MEDVi’s clinical partner, suffered a data breach in January 2026 exposing 1.6 million patient records. A security researcher found that changing a number in a URL allowed access to any patient’s complete medical record.
Common Side Effects of GLP-1 Medications
| Side Effect | Approximate Incidence |
|---|---|
| Nausea | ~37% |
| Fatigue | ~17% |
| Vomiting | ~16% |
| Constipation | ~15% |
| Diarrhea | ~13% |
Who Should Exercise Extreme Caution
- Anyone who wants FDA-approved products — MEDVi sells compounded products only
- Patients who need responsive customer support — billing and cancellation complaints are widespread
- Anyone uncomfortable with AI-generated marketing — fake doctors and fabricated photos are documented
- Patients who value data privacy — the OpenLoop breach exposed 1.6 million records
- Anyone who cannot afford to lose their investment — refunds require 5 months of participation and deduct 25%
- Patients considering oral tirzepatide — the class action lawsuit alleges it was marketed unlawfully
Who Should Consider MEDVi
MEDVi may appeal to self-sufficient, healthy patients who want the lowest possible entry price for compounded GLP-1 medication, who are comfortable with AI-driven customer service, and who will verify every cost and cancellation term in writing before enrolling. The platform is LegitScript certified, the video consultations are genuinely conducted by licensed clinicians, and the flat-rate refill pricing at $299/month is competitive.
Who Should Look Elsewhere
You should consider a different provider if you want FDA-approved products, responsive human customer support, a clean regulatory record, or data privacy protection. Anyone who was alarmed by the fake doctor allegations, the data breach, or the FDA warning letter should look at established providers with verified track records.
Final Verdict
Strengths
- ✅ Lowest first-month entry price in the market — $179 for compounded semaglutide
- ✅ LegitScript certified — independent third-party compliance verification
- ✅ Flat-rate refill pricing — $299/month for semaglutide regardless of dose
- ✅ Oral tablet options available — for patients who prefer not to inject
- ✅ Mandatory video consultation — not purely asynchronous
- ✅ Lifestyle coaching included at no extra cost
- ✅ Lab work included but not required
- ✅ 11,400+ Trustpilot reviews with a 4.4–4.5 average on the main page
- ✅ $401 million in 2025 revenue independently verified by The New York Times
Weaknesses
- ⚠️ FDA Warning Letter (February 2026) for misbranding compounded GLP-1 products
- ⚠️ Data breach (January 2026) exposed 1.6 million patient records through OpenLoop Health
- ⚠️ Class action lawsuit (November 2025) regarding compounded oral tirzepatide
- ⚠️ AI-generated fake doctors — 800+ Facebook accounts posing as physicians
- ⚠️ Fabricated before-and-after photos — stolen from a Redditor who lost weight in the mid-2010s
- ⚠️ Fake doctor endorsements — a real doctor demanded removal from the site
- ⚠️ Billing complaints — auto-renewal confusion, charges after cancellation
- ⚠️ Restrictive refund policy — requires 5 months of participation and deducts 25%
- ⚠️ Bait-and-switch pricing — first month advertised at $179, ongoing at $299–$399
- ⚠️ BBB rating of F — not accredited
- ⚠️ Trustpilot rating of 2.3/5 on the GLP subdomain
- ⚠️ AI chatbot fabricated drug prices and hallucinated product lines
- ⚠️ Hardcoded patient emails in public JavaScript — 999 addresses exposed
Who May Benefit
Self-sufficient patients who understand that MEDVi is a marketing layer on top of white-label infrastructure, who will verify all costs before enrolling, and who are comfortable with the risks of compounded products and AI-driven operations may find the low entry price attractive. The video consultations are conducted by real clinicians, and the medication does arrive for most patients.
Who Should Avoid
- Patients who want FDA-approved products
- Anyone who needs responsive human customer support
- Anyone concerned about data privacy
- Patients who may need a refund
- Anyone considering oral tirzepatide
- Anyone who cannot tolerate the risk of a company with an FDA warning letter, a data breach, and a class action lawsuit
Overall Recommendation
Rating: 2.5 out of 5 Stars
MEDVi offers the lowest first-month entry price in the compounded GLP-1 market, with LegitScript certification, mandatory video consultations with licensed clinicians, and flat-rate refill pricing at $299/month. The company generated $401 million in revenue in 2025 with just two employees, a feat of AI-driven operational efficiency that Forbes and The New York Times both profiled. However, the platform has accumulated a series of serious problems that cannot be overlooked: an FDA Warning Letter for misbranding, a data breach exposing 1.6 million patient records, a class action lawsuit over compounded oral tirzepatide, and investigations documenting AI-generated fake doctors, fabricated before-and-after photos, and 800+ fake Facebook accounts. Consumer complaints about billing, auto-renewal, and cancellation are widespread. For patients who prioritize price above all else and will verify every term in writing, MEDVi is a viable option. For everyone else, the regulatory, legal, and ethical concerns make this a platform to approach with extreme caution — or avoid entirely.
Frequently Asked Questions
Is MEDVi legit?
MEDVi is a real, operating telehealth platform with LegitScript certification and independently verified revenue. It is not a scam in the conventional sense. However, it has received an FDA Warning Letter, suffered a data breach through its clinical partner, and faces a class action lawsuit. The company’s marketing has used AI-generated fake doctors and fabricated before-and-after photos.
How much does MEDVi cost?
Compounded semaglutide injections start at $179 for the first month, then $299/month ongoing. Compounded semaglutide tablets are $249/month. Compounded tirzepatide injections start at $349/month. Compounded tirzepatide tablets are $279/month. Billing occurs every 28 days, resulting in 13 charges per year.
What medications does MEDVi prescribe?
Compounded semaglutide and compounded tirzepatide in both injectable and oral tablet formats. Both are compounded versions and are not FDA-approved.
Does MEDVi accept insurance?
No. MEDVi is a cash-pay service.
Did MEDVi receive an FDA warning letter?
Yes. On February 20, 2026, the FDA issued a Warning Letter to MEDVi for misbranding violations, including false claims of FDA approval and false representation as the compounder of its compounded products.
What was the MEDVi data breach?
In January 2026, OpenLoop Health — MEDVi’s clinical partner — suffered a data breach exposing 1.6 million patient records. A security researcher found that changing a number in a URL allowed access to any patient’s complete medical record.
Is there a lawsuit against MEDVi?
Yes. A class action lawsuit filed in Delaware in November 2025 (Day v. OpenLoop Health Inc.) alleges that compounded oral tirzepatide sold through MEDVi was falsely represented as safe and effective and was sold without required FDA approval.
Are the doctors on MEDVi real?
Business Insider found that MEDVi’s advertising was “fueled by ads from doctors who don’t appear to exist,” with at least six purported doctor pages marketing the products. Futurism found AI-deepfaked images of phony patients and AI-generated doctors in MEDVi-branded lab coats.
What is MEDVi’s refund policy?
Refunds require demonstrating no weight loss after 5 months of following the program and deduct a 25% consultation fee. Prescription products are non-refundable.
How do I cancel MEDVi?
Cancellation requires 72 hours notice before the billing date. It can be done through the patient portal or by contacting customer service.
Does MEDVi sell FDA-approved products?
No. MEDVi sells compounded semaglutide and tirzepatide, which are not FDA-approved. The FDA specifically cited MEDVi for claiming its products had the “same active ingredient” as FDA-approved drugs, which the agency said falsely implied FDA evaluation.
Who founded MEDVi?
Matthew Gallagher, a 41-year-old entrepreneur, founded MEDVi in September 2024 with $20,000 and a collection of AI tools including ChatGPT, Claude, Grok, Midjourney, Runway, and ElevenLabs.
What is MEDVi’s BBB rating?
MEDVi has an F rating from the Better Business Bureau and is not accredited.
Is MEDVi LegitScript certified?
Yes. MEDVi holds active LegitScript certification, an independent third-party verification that requires ongoing compliance monitoring.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved. MEDVi has received an FDA Warning Letter, suffered a data breach through its clinical partner, and faces a class action lawsuit. Always consult a qualified healthcare professional before starting any new medication or treatment, especially if you have existing health conditions, take medications, or are pregnant or nursing. Individual results may vary.
